• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Intertek banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

CDMO Micro-Sphere expands its inhalation capabilities

Swiss CDMO Micro-Sphere, which specializes in spray drying and capsule filling, has announced a greater than €5 million expansion of its Monteggio, Switzerland GMP manufacturing facility that includes new inhalation testing laboratory space as well as a containment system for handling high potency compounds. Micro-Sphere also announced that its manufacturing license has been renewed with the addition of biologics.

The company, which expanded its DPI capsule filling capacity in 2018 and added a fifth spray drying line at the Monteggio facility in 2019, says that it has invested approximately €30 million in the facility since 2017. According to Facility Head Matteo Berlusconi, equipment added in the past year includes two additional MG2 capsule filling machines, a Malvern Mastersizer 3000 for particle size analysis, and a second PSD-2 spray dryer.

Berlusconi commented, “This latest investment is another example of how we continue to invest and grow to serve market requirements and work with our clients to improve drug development and delivery. We will continue to respond to industry demand and our ability to take on more complex and larger-scale projects at the site is already moving to the next level with a new R&D department to offer formulation development expertise and focused on inhalation formulation development expected to be operational by the end of Q4 2022.”

Micro-Sphere Managing Director Michael Grassberger said, “The use of highly potent compounds is becoming increasingly common across the market and at present there are very few CDMOs offering this level of capability, especially when combined with our experience and expertise. This facility expansion, together with our track record in the industry, strengthens our ability to produce both clinical and commercial products whilst delivering a seamless experience to our customers across the globe.” 

Share

published on October 24, 2022

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Solstice Air banner
    © 2025 OINDPnews